milnacipran has been researched along with cabergoline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Inoue, T; Izumi, T; Kitaichi, Y; Koyama, T; Masui, T; Nakagawa, S; Tanaka, T | 1 |
1 review(s) available for milnacipran and cabergoline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for milnacipran and cabergoline
| Article | Year |
|---|---|
Effect of co-administration of a serotonin-noradrenaline reuptake inhibitor and a dopamine agonist on extracellular monoamine concentrations in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Biogenic Monoamines; Cabergoline; Cyclopropanes; Dopamine; Dopamine Agonists; Drug Interactions; Ergolines; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Microdialysis; Milnacipran; Norepinephrine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Time Factors | 2008 |